Meet an Unreasonable Venture
CyanoCapture
Bringing affordable carbon capture to emitting industries worldwide.
Over 27% of the FDA's list of essential drugs were categorised as 'at risk'. CyanoCapture's photosynthetic biomanufacturing platform makes it possible to synthesise $40bn worth of drug molecules in short supply, affordably for customers around the world. The technology uses cutting-edge ML tools, genomic and transcriptomic datasets to genetically programme fast-growing photosynthetic cells to secrete drug molecules designed by the user.
Notable Achievements
- Raised $4.49M in equity financing from VCs and angels and a further $5M in non-dilutive prizes.
- Secured $27m in LOIs and pre-orders.
- Winner - Elon Musk's XPRIZE 2021.
Currently Operating in One Region
Press Mentions
February 18, 2026
CyanoCapture and Persist AI Announce Strategic Collaboration to Build World's First Robotic GMP Facility for Oral Protein and Peptide Drugs
CyanoCapture has partnered with Persist AI to develop the world's first robotic GMP facility for producing oral protein and peptide drugs. This collaboration highlights CyanoCapture's commitment to...
Read more »
October 30, 2025
Liverpool, CyanoCapture Team Up for Bionanotech Breakthrough
CyanoCapture collaborates with Liverpool researchers to advance bionanotechnology, focusing on enhancing carbon capture technologies through innovative cyanobacteria. This partnership aims to...
Read on Mirage News »More Ventures in Energy & Environment
Get the Unreasonable Newsletter
Get monthly updates on CyanoCapture and all of the other ventures working to solve global challenges.